|
|
|
|
|
|
By Christian Marsolais, Ph.D., and Michel Demeule, Ph.D., Theratechnologies | Peptide-drug conjugates — therapies that generally employ a cleavable or non-cleavable linker to attach a receptor-targeting peptide to a drug payload — have emerged as a potentially viable modality for targeted cancer treatment. How do they work? And how is the glycoprotein SORT1 one of the most promising targets? |
|
|
Patenting Functionally Claimed Biological Compounds After Amgen V. Sanofi | By Jonathan B. (J.B.) Fitzgerald, Ph.D., and Trent L. Hoffman | Snell & Wilmer attorneys discuss the recent SCOTUS decision to uphold the Federal Circuit's holding that Amgen’s patent claims for functionally claimed antibodies were invalid for failing to meet the enablement requirement. The attorneys share what this means for the industry going forward. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
